Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the antitumor efficacy and safety of bendamustine
(SyB L-0501: 90 mg/m^2/day) for a maximum of 6 cycles (1 cycle: intravenous administration
for 2 consecutive days and 26-day observation period) in patients with relapsed/refractory
multiple myeloma.